Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

AZ adds cancer vaccine to immuno-oncology portfolio

Firm's biologics unit adds to string of oncology deals in 2015

- PMLiVE

Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

Will acquire Therakos to further boost its hospital drug portfolio

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

- PMLiVE

Pharma healthier than it appears, says report

Thomson Reuters research finds global pharma sales will hit $1.3trn by 2018

Bristol-Myers Squibb (BMS) building

BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

Rounds off a week of deals in the immunotherapy space for big pharma

- PMLiVE

Hints of recovery at GSK as group sales climb

Drug revenue still falling but vaccines and HIV drugs help offset Advair decline

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

Sanofi reception

Sanofi and Regeneron extend partnership to cancer

Sanofi will pay more than $2bn to the firm for immunotherapy research

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links